These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 20576794)
1. Significance of serum concentrations of E-selectin and CA19-9 in the prognosis of colorectal cancer. Sato H; Usuda N; Kuroda M; Hashimoto S; Maruta M; Maeda K Jpn J Clin Oncol; 2010 Nov; 40(11):1073-80. PubMed ID: 20576794 [TBL] [Abstract][Full Text] [Related]
2. Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer? Chen CC; Yang SH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Chang SC J Surg Res; 2005 Apr; 124(2):169-74. PubMed ID: 15820244 [TBL] [Abstract][Full Text] [Related]
3. Preoperative serum level of CA19-9 predicts recurrence after curative surgery in node-negative colorectal cancer patients. Nakagoe T; Sawai T; Tsuji T; Jibiki MA; Nanashima A; Yamaguchi H; Yasutake T; Ayabe H; Arisawa K Hepatogastroenterology; 2003; 50(51):696-9. PubMed ID: 12828063 [TBL] [Abstract][Full Text] [Related]
4. CA19-9 as the most significant prognostic indicator of metastatic colorectal cancer. Wang WS; Lin JK; Chiou TJ; Liu JH; Fan FS; Yen CC; Lin TC; Jiang JK; Yang SH; Wang HS; Chen PM Hepatogastroenterology; 2002; 49(43):160-4. PubMed ID: 11941943 [TBL] [Abstract][Full Text] [Related]
5. Serum carcinoembryonic antigen monitoring after curative resection for colorectal cancer: clinical significance of the preoperative level. Park IJ; Choi GS; Lim KH; Kang BM; Jun SH Ann Surg Oncol; 2009 Nov; 16(11):3087-93. PubMed ID: 19629600 [TBL] [Abstract][Full Text] [Related]
6. Clinical significance of CEA and CA19-9 in postoperative follow-up of colorectal cancer. Yakabe T; Nakafusa Y; Sumi K; Miyoshi A; Kitajima Y; Sato S; Noshiro H; Miyazaki K Ann Surg Oncol; 2010 Sep; 17(9):2349-56. PubMed ID: 20217258 [TBL] [Abstract][Full Text] [Related]
7. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer. Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694 [TBL] [Abstract][Full Text] [Related]
8. Serum p53 antibody as tumor marker for follow-up of colorectal cancer after curative resection. Tang R; Yeh CY; Wang JY; Changchien CR; Chen JS; Hsieh LL Ann Surg Oncol; 2009 Sep; 16(9):2516-23. PubMed ID: 19565285 [TBL] [Abstract][Full Text] [Related]
9. High serum soluble E-selectin levels are associated with postoperative haematogenic recurrence in esophageal squamous cell carcinoma patients. Shimada Y; Maeda M; Watanabe G; Imamura M Oncol Rep; 2003; 10(4):991-5. PubMed ID: 12792758 [TBL] [Abstract][Full Text] [Related]
10. Comparative analysis of predictive biomarkers for therapeutical strategies in colorectal cancer. Gasser M; Gerstlauer C; Grimm M; Bueter M; Lebedeva T; Lutz J; Maeder U; Ribas C; Ribas C; Nichiporuk E; Thalheimer A; Heemann U; Thiede A; Meyer D; Waaga-Gasser AM Ann Surg Oncol; 2007 Apr; 14(4):1272-84. PubMed ID: 17211733 [TBL] [Abstract][Full Text] [Related]
11. Value of serum carbohydrate antigen 19-9 for predicting extrahepatic metastasis in patients with liver metastasis from colorectal carcinoma. Sasaki A; Kawano K; Inomata M; Shibata K; Matsumoto T; Kitano S Hepatogastroenterology; 2005; 52(66):1814-9. PubMed ID: 16334783 [TBL] [Abstract][Full Text] [Related]
12. The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer. Kinsella TJ; Seo Y; Willis J; Stellato TA; Siegel CT; Harpp D; Willson JK; Gibbons J; Sanabria JR; Hardacre JM; Schulak JP Am J Clin Oncol; 2008 Oct; 31(5):446-53. PubMed ID: 18838880 [TBL] [Abstract][Full Text] [Related]
13. Serum levels of soluble E-selectin in colorectal cancer. Uner A; Akcali Z; Unsal D Neoplasma; 2004; 51(4):269-74. PubMed ID: 15254658 [TBL] [Abstract][Full Text] [Related]
14. Slope analysis of CA19-9 and CEA for predicting recurrence in colorectal cancer patients. Nakayama T; Watanabe M; Teramoto T; Kitajima M Anticancer Res; 1997; 17(2B):1379-82. PubMed ID: 9137502 [TBL] [Abstract][Full Text] [Related]
15. Preoperative serum levels of CEA and CA 19-9 and their prognostic significance in colorectal carcinoma. Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Pahl H; Fateh-Moghadam A Anticancer Res; 1997; 17(4B):2935-8. PubMed ID: 9329568 [TBL] [Abstract][Full Text] [Related]
16. Prognostic value of serum tumor antigen CA19-9 after curative resection of colorectal cancer. Park IJ; Choi GS; Jun SH Anticancer Res; 2009 Oct; 29(10):4303-8. PubMed ID: 19846991 [TBL] [Abstract][Full Text] [Related]
17. Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers. Guadagni F; Kantor J; Aloe S; Carone MD; Spila A; D'Alessandro R; Abbolito MR; Cosimelli M; Graziano F; Carboni F; Carlini S; Perri P; Sciarretta F; Greiner JW; Kashmiri SV; Steinberg SM; Roselli M; Schlom J Cancer Res; 2001 Mar; 61(6):2523-32. PubMed ID: 11289125 [TBL] [Abstract][Full Text] [Related]
18. Serum protein expression predicts recurrence in patients with early-stage lung cancer after resection. D'Amico TA; Brooks KR; Joshi MB; Conlon D; Herndon J; Petersen RP; Harpole DH Ann Thorac Surg; 2006 Jun; 81(6):1982-7; discussion 1987. PubMed ID: 16731117 [TBL] [Abstract][Full Text] [Related]
19. Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma. Berger AC; Meszoely IM; Ross EA; Watson JC; Hoffman JP Ann Surg Oncol; 2004 Jul; 11(7):644-9. PubMed ID: 15197014 [TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of preoperative serum CA 19.9 assay in patients with colorectal carcinoma. Diez M; Cerdán FJ; Pollán M; Maestro ML; Ortega MD; Martínez S; Moreno G; Balibrea JL Anticancer Res; 1994; 14(6B):2819-25. PubMed ID: 7872725 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]